Sign Up
Stories
Myasthenia Gravis: FDA Approval and Positive Opinions
Share
ANJESO Drug Insight and Market Forecast
Biosimilar Partnership in U.S.
Biotech Drug Trials Face Setbacks
Overview
API
FDA approves zilucoplan, a complement inhibitor for generalized myasthenia gravis, while argenx receives positive opinions from Health Canada and the European Medicines Agency for its neonatal Fc receptor (FcRn) blocker, VYVGART, for the same condition.
Ask a question
How do the recent advancements in myasthenia gravis treatment reflect broader trends in the healthcare industry, particularly in the development of targeted therapies and personalized medicine?
How might the FDA approval of zilucoplan impact the treatment landscape for generalized myasthenia gravis, and what are the potential implications for patients and healthcare providers?
What are the implications of argenx receiving positive opinions from Health Canada and the European Medicines Agency for its neonatal Fc receptor (FcRn) blocker, VYVGART, for the treatment of generalized myasthenia gravis?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage